AGEN

Agenus Inc

7.15

Nov 06 • 3:59 PM ET +0.71 (11.02%)

7.05

Aftermarket • 7:48 PM ET -0.10 (-1.40%)

Healthcare Biotechnology USA Small NASD

Nov 06, 9:06 AMAgenus reports >50% long-term survival in refractory MSS metastatic colorectal cancer with botensilimab plus balstilimab in SITC 2026 data

Peers: XLO CHRS CMPX RCUS ALXO HOWL IOVA IMCR ONCY EXEL

| Held by: VTI IWM VXF VTWO IWN VFMO FDM IWC IWO VTWV

Scroll to Statements

Index	RUT
Market Cap	323.51M
Enterprise Value	507.18M
Income	29.46M
Sales	133.95M
Book/sh	-2.33
Cash/sh	1.92
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	81
IPO	Feb 04, 2000

P/E	9.85
Forward P/E	-
PEG	-
P/S	2.42
P/B	-
P/C	3.72
P/FCF	-
EV/EBITDA	9.33
EV/Sales	3.79
Quick Ratio	0.73
Current Ratio	0.73
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	0.73
EPS next Y	-0.61
EPS next Q	-0.34
EPS this Y	113.95%
EPS next Y	-332.08%
EPS next 5Y	32.16%
EPS past 3/5Y	93.99% 82.55%
Sales past 3/5Y	5.22% 5.31%
EPS Y/Y TTM	138.02%
Sales Y/Y TTM	25.38%
EPS Q/Q	-99.06%
Sales Q/Q	4.14%
Earnings	Nov 05 BMO
EPS/Sales Surpr.	0.00% 11.70%

Insider Own	11.61%
Insider Trans	0.00%
Inst Own	36.91%
Inst Trans	17.50%
ROA	12.38%
ROE	-
ROIC	62.80%
Gross Margin	98.35%
Oper. Margin	38.94%
Profit Margin	21.99%
SMA20	7.46%
SMA50	-4.16%
SMA200	42.65%
Trades

Shs Outstand	45.21M
Shs Float	39.92M
Short Float	17.54%
Short Ratio	6.75
Short Interest	7.00M
52W High	10.31 -30.65%
52W Low	2.71 163.84%
Volatility	8.33% 7.22%
ATR (14)	0.53
RSI (14)	51.84
Beta	1.52
Rel Volume	0.84
Avg Volume	1.04M
Volume	873,711

Perf Week	4.53%
Perf Month	-5.17%
Perf Quarter	2.14%
Perf Half Y	87.17%
Perf YTD	127.71%
Perf Year	86.20%
Perf 3Y	-54.26%
Perf 5Y	-91.24%
Perf 10Y	-90.89%
Recom	1.00
Target Price	25.00
Prev Close	6.44
Price	7.15
Change %	11.02%

Consensus

Strong Buy

Avg. Price Target

$25.00

Implied Upside

+249.7%

Analysts10incl. previous ratings

Rating Distribution8 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 28, 2026	Initiated	RRodman & Renshaw	Buy	$19	+165.7%
Sep 18, 2026	Initiated	CChardan Capital Markets	Buy	$40	+459.4%
Jul 13, 2026	Reiterated	HH.C. Wainwright	Buy	$23 → $30	+319.6%
Jun 04, 2025	Upgrade	HH.C. Wainwright	Neutral → Buy	$25	+249.7%
Jul 19, 2024	Downgrade	RRobert W. Baird	Outperform → Neutral	$35 → $8	+11.9%
Jul 18, 2024	Downgrade	WWilliam Blair	Outperform → Mkt Perform
Jul 18, 2024	Downgrade	HH.C. Wainwright	Buy → Neutral	$9	+25.9%
Jun 06, 2023	Initiated	RRobert W. Baird	Outperform	$8	+11.9%
Jun 06, 2023	Initiated	RRobert W. Baird	Outperform	$60 → $80	+1,018.9%
Feb 28, 2023	Resumed	HH.C. Wainwright	Buy	$8	+11.9%
Sep 28, 2022	Initiated	SSMBC Nikko	Outperform	$5	-30.1%
Dec 16, 2021	Initiated	HH.C. Wainwright	Buy	$12	+67.8%
Nov 19, 2019	Resumed	BB. Riley FBR	Buy	$6	-16.1%
Apr 22, 2019	Initiated	BB. Riley FBR	Buy
Oct 28, 2016	Downgrade	HH.C. Wainwright	Buy → Neutral	$10 → $5	-30.1%
Oct 27, 2016	Reiterated	MMaxim Group	Buy
Mar 11, 2016	Upgrade	MMaxim Group	Hold → Buy	$7	-2.1%
Dec 16, 2015	Initiated	JJefferies	Buy
Oct 27, 2015	Downgrade	MMaxim Group	Buy → Hold
Jul 27, 2015	Reiterated	MMLV & Co	Buy	$9 → $11	+53.8%

Nov-06-26 08:00AM	Agenus Reports More Than Half of Patients with Refractory MSS Metastatic Colorectal Cancer Achieved Long-Term Survival Following BOT+BAL Treatment at SITC 2026 (Business Wire) +11.02%
Nov-05-26 06:39PM	Agenus: Q3 Earnings Snapshot (Associated Press) -7.60%
06:30AM	Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN Study (Business Wire)
Nov-02-26 06:05PM	Agenus to Participate in Rodman & Renshaw Virtual Fireside Chat (Business Wire)
05:42AM	Agenus Announces Nature Medicine Publication of Multicenter UNICORN Phase 2 Trial Demonstrating Deep Responses with Neoadjuvant BOT+BAL in Resectable Colon Cancer (Business Wire)
01:04PM	Loading…
Oct-28-26 01:04PM	Agenus Faces A Breakeven Test As Sentiment Turns Bullish Despite A Sliding Stock (Earnings Whispers) +7.22%
Oct-25-26 07:00AM	Agenus Reports 72% of Patients with Locally Advanced dMMR Colon Cancer Had No Cancer Remaining at Surgery Following Six Weeks of BOT+BAL in Phase 2 NEOASIS Study at ESMO 2026 (Business Wire)
Oct-22-26 04:30PM	Agenus to Provide Third Quarter 2026 Financial Report and Development Update (Business Wire)
Oct-09-26 03:23PM	Agenus to Participate in Chardan's 10th Annual Healthcare Investor Conference (Business Wire)
Oct-08-26 07:30AM	Armenia Grants First Marketing Authorizations for Agenus' BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer (Business Wire)
Oct-03-26 10:50AM	Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 (Business Wire)
Oct-02-26 09:00AM	Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026 (Business Wire)
Sep-10-26 07:30AM	Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026 (Business Wire)
Aug-31-26 07:30AM	Agenus to Participate in Upcoming September Investor Conferences (Business Wire)
Aug-28-26 10:07AM	Agenus Announces Peer-Reviewed Publication Linking BOT+BAL's Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism (Business Wire)
10:05AM	Loading…
Aug-26-26 10:05AM	Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer (Business Wire)
Aug-07-26 04:42PM	Agenus: Q2 Earnings Snapshot (Associated Press) -7.08%
Aug-06-26 07:30AM	Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer (Business Wire)
Jul-28-26 04:30PM	Agenus to Provide Second Quarter 2026 Financial Report and Development Update (Business Wire) +7.67%
Jul-17-26 10:28AM	Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026 (Business Wire)
Jul-13-26 02:25PM	AGEN Stock Eyes Best Day Ever Following Strategic Shift To Earlier Colon Cancer Treatment (Stocktwits) +82.69%
12:53PM	Agenus shares surge as company secures up to $340M to advance colon cancer trial (Proactive)
08:25AM	Agenus Shares Rise After Securing Up to $340 Million Financing Package (AGEN) (Investors Hub)
08:24AM	Wall Street closes lower as chip selloff and oil surge weigh on markets (Proactive)
08:24AM	Nasdaq falls, Dow slips as oil prices rebound on fresh US-Iran fighting (Proactive)
07:46AM	Agenus surges on study pivot; Apnimed lines up an IPO (BioPharma Dive)
06:59AM	Agenus rises premarket; Micron, Western Digital slide (Investing.com)
06:00AM	Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer (Business Wire)
Jul-06-26 07:30AM	Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026 (Business Wire)
Jun-25-26 07:00AM	Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026 (Business Wire)
04:30PM	Loading…
Jun-02-26 04:30PM	Agenus Announces Virtual 2026 Annual Shareholders Meeting (Business Wire)
May-21-26 05:00PM	Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026 (Business Wire)
05:00PM	Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC (Business Wire)
May-15-26 04:11PM	Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer (Business Wire) -11.73%
May-11-26 05:27PM	Agenus: Q1 Earnings Snapshot (Associated Press) -14.66% +5.52%
08:45AM	Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development (Business Wire)
May-04-26 04:30PM	Agenus to Provide First Quarter 2026 Financial Report and Corporate Update (Business Wire)
Apr-21-26 10:00AM	Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026 (Business Wire) -11.54%
08:00AM	Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs (Business Wire)
Apr-17-26 04:43PM	Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer (Business Wire) -7.72%
Apr-03-26 07:30AM	Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026 (Business Wire)
Apr-01-26 07:30AM	Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer (Business Wire)
Mar-26-26 04:52PM	Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access (Business Wire)
Mar-17-26 04:40PM	Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer (Business Wire) +21.28% -5.76%
Mar-16-26 07:41PM	Agenus: Q4 Earnings Snapshot (Associated Press Finance) +6.13%
07:30AM	Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized (Business Wire)
Mar-10-26 07:30AM	Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs (Business Wire) +6.98%
Mar-04-26 04:30PM	Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update (Business Wire) -8.75%
Feb-24-26 09:33AM	Agenus (AGEN) Presents New Phase 1b Clinical Data on BOT/BAL Combination for MSS mCRC (Insider Monkey)
Feb-19-26 03:15PM	Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL (Business Wire)
Feb-09-26 01:00PM	Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors (Business Wire)
Jan-28-26 08:00PM	Agenus Webcast: Zydus Manufacturing Deal Closes, France Access Expands, Phase 3 BATMAN Nears Launch (MarketBeat)
Jan-21-26 07:30AM	Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab (Business Wire)
Jan-20-26 06:24PM	Agenus to Host First 2026 Stakeholder Webcast (Business Wire)
Jan-16-26 06:16AM	Agenus and Zydus complete $141m BOT+BAL immunotherapy collaboration deal (Pharmaceutical Business Review) -9.24%
Jan-15-26 07:01AM	Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness (Business Wire) -21.37%
Jan-13-26 12:00PM	Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock? (Zacks) +8.47%
09:40AM	Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year? (Zacks)
Jan-12-26 07:30AM	France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas (Business Wire) +8.70%
Dec-23-25 08:05AM	Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC (Business Wire) -5.70%
Nov-19-25 04:01PM	Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL (Business Wire)
Nov-18-25 08:41AM	Agenus Appoints Dr. Jose Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC (Business Wire)
Nov-10-25 08:40AM	Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates (Zacks) +5.78%
07:37AM	Agenus: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances (Business Wire)
Nov-06-25 05:20PM	Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-05-25 06:40PM	Innoviva (INVA) Q3 Earnings and Revenues Beat Estimates (Zacks)
01:47PM	Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report (Business Wire)
Nov-03-25 05:20PM	Sarepta Therapeutics (SRPT) Reports Q3 Loss, Beats Revenue Estimates (Zacks) -6.05%
Oct-17-25 08:00AM	Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025 (Business Wire)
Oct-16-25 07:48AM	Agenus to Host October Stakeholder Briefing Showcasing BOT/BAL Global Momentum and Post-ESMO Insights (Business Wire)
Sep-23-25 10:14AM	Are Options Traders Betting on a Big Move in Agenus tock? (Zacks)
Sep-09-25 07:43AM	France Grants Reimbursed Compassionate Access (AAC) for Agenus BOT/BAL in Refractory MSS Metastatic Colorectal Cancer (Business Wire) +19.01%
Sep-05-25 08:52AM	Agenus to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire)
Aug-28-25 10:44AM	FDA Tightens Survival Standards as Cancer Drug Pipeline Hits $866B Market Milestone (PR Newswire) -6.39%
Aug-26-25 09:37AM	Update: Agenus Aug 27 Stakeholder Webcast-Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight (Business Wire) +5.47%
09:19AM	What To Expect From Agenus Inc (AGEN) Q2 2025 Earnings (GuruFocus.com)
Aug-19-25 07:30AM	Agenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025 (Business Wire)
Aug-11-25 06:55PM	Agenus (AGEN) Reports Q2 Loss, Beats Revenue Estimates (Zacks) -11.04% +12.65%
06:06PM	Agenus: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Agenus Announces Second Quarter 2025 Financial Results and Virtual Meeting to Discuss Strategic Progress (Business Wire)
Aug-07-25 05:40PM	Gilead Sciences (GILD) Tops Q2 Earnings and Revenue Estimates (Zacks)
Aug-06-25 05:25PM	AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates (Zacks) -10.02%
Aug-01-25 09:05AM	Zacks.com featured highlights include QuantumScape, Civeo and Agenus (Zacks)
Jul-31-25 03:00PM	QuantumScape & 2 Other Stocks to Buy for Earnings Acceleration (Zacks) -6.44%
07:30AM	Agenus to Provide Corporate Update and Second Quarter 2025 Financial Report (Business Wire)
Jul-30-25 09:40AM	Is CVS Health (CVS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-29-25 03:46PM	Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments (PR Newswire) -7.40%
Jul-25-25 12:46PM	Agenus to Highlight Emerging Survival Plateaus with Botensilimab/Balstilimab in Oral Presentation of Study in Refractory Patients Across Five Tumor Types at ESMO 2025 (Business Wire)
Jul-24-25 10:45AM	VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales (Zacks)
Jul-22-25 09:15AM	From Diagnosis to Surgery: How AI Tech Is Quietly Reshaping Healthcare Profits (PR Newswire)
Jul-17-25 01:07PM	AstraZeneca's AL Amyloidosis Drug Misses Goal in Late-Stage Studies (Zacks) +5.66%
11:34AM	MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights (Zacks)
07:00AM	US FDA Approves GSKs SHINGRIX in a Prefilled Syringe Presentation (Business Wire)
Jul-15-25 08:32AM	AstraZeneca Meets All Key Goals in Phase III Hypertension Study (Zacks) -8.93%
08:28AM	Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIA (Zacks)
Jul-14-25 09:40AM	Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:39AM	Agenus (AGEN) Surges 19.3%: Is This an Indication of Further Gains? (Zacks)
Jul-11-25 07:30AM	MiNK Therapeutics Announces Publication of Complete Remission Following Allogeneic iNKT Cell Therapy in Metastatic Testicular Cancer (GlobeNewswire) +19.26%
Jul-10-25 09:11AM	KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally? (Zacks) +14.29%

Show Previous News

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

FounderDr. Garo H. Armen Ph.D.

Ph.D.Dr. Steven J. O'Day M.D.

Director and President & CEO of MiNK TherapeuticsDr. Jennifer S. Buell Ph.D.

Chief Information OfficerCraig Winter

Vice President of Investor Relations & Corporate DevelopmentMr. Zack Armen

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AGEN

Agenus Inc

Upgrade your Finviz experience